NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, SOUTH AFRICA, CANADA, JAPAN
Utrecht (The Netherlands) – Gilde Healthcare company Nyxoah (the “Company”) a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions, today announces the results of its initial public offering of new shares, launched on 9 September 2020, with the admission of all of its shares to trading on the regulated market of Euronext Brussels under the symbol “NYXH”.
The final offering price for the Offering has been set at €17.00 per share, giving the Company an initial market capitalization of approximately €364.21 million, or approximately €375.26 million assuming the exercise in full of the Over-allotment Option. Gross proceeds for the Company from the Offering will amount to approximately €73.70 million, or approximately €84.75 million (US$100m), assuming the exercise in full of the Over-allotment Option. Nyxoah has currently obtained reimbursement in Germany under the existing NUB (Neue Untersuchungs- und Behandlungsmethoden) system for HGNS, generating its first revenue and is further preparing commercial market entrance in focused European countries. Nyxoah has recently obtained approval by the FDA (the Food and Drug Administration) to initiate its DREAM IDE (Investigational Device Exemption) pivotal trial. First US patient enrolments are expected to take place in 2020.
Trading of Nyxoah’s Shares on the regulated market of Euronext Brussels under the symbol “NYXH” is expected to commence, on an “if-and-when-issued-and/or-delivered” basis, on or about 18 September 2020. Degroof Petercam NV/SA and Belfius Bank NV/SA acted as Joint Global Coordinators and Joint Bookrunners in connection with the Offering.
Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep disordered breathing conditions. Nyxoah’s lead solution is the Genio® system, a CE-validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.
For more information, please visit www.nyxoah.com.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, medtech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.